

# SCHEDULE 14A INFORMATION

## Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant  Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

## PROTEOSTASIS THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box)

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1. Title of each class of securities to which transaction applies:
2. Aggregate number of securities to which transaction applies:
3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4. Proposed maximum aggregate value of transaction:
5. Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1. Amount Previously Paid:
2. Form, Schedule or Registration Statement No.:
3. Filing Party:
4. Date Filed:

**PROTEOSTASIS THERAPEUTICS, INC.**

**80 Guest Street  
Suite 500  
Boston, Massachusetts 02135**

**SUPPLEMENT TO  
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS  
AND PROXY STATEMENT, DATED APRIL 29, 2020**

**FOR THE VIRTUAL ANNUAL MEETING OF STOCKHOLDERS  
TO BE HELD ON JUNE 29, 2020**

This supplement (the “Supplement”) provides updated information with respect to the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Proteostasis Therapeutics, Inc. (the “Company”) to be held on June 29, 2020.

On April 29, 2020, the Company commenced distribution to its stockholders a Notice of the 2020 Annual Meeting of Stockholders and Definitive Proxy Statement (the “Notice and Proxy Statement”) for the Annual Meeting. This Supplement, including the press release dated June 5, 2020 included below, which describes a change in the location of the Annual Meeting from an in-person to a virtual-only meeting, should be read in conjunction with the Notice and Proxy Statement. Except as specifically revised by the information contained herein, this Supplement does not revise or update any of the other information set forth in the Notice and Proxy Statement.

**NOTICE OF CHANGE OF LOCATION  
OF ANNUAL MEETING OF STOCKHOLDERS  
TO BE HELD ON JUNE 29, 2020**

**Proteostasis Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders**

BOSTON, Mass. – June 5, 2020 – Proteostasis Therapeutics, Inc. (Nasdaq: PTI) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

The previously announced date and time of the Annual Meeting, Monday, June 29, 2020, at 9:00 a.m. Eastern Time, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement, has not changed. Online access to the Annual Meeting will begin at approximately 8:45 a.m. Eastern Time. Stockholders will not be able to attend the Annual Meeting in person.

**Attending the Virtual Meeting as a Stockholder of Record**

The Company’s stockholders of record as of April 30, 2020 (the “Record Date”) can register to attend the Annual Meeting by accessing the meeting center at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI) and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. You will need to register to attend the Annual Meeting at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI) by no later than Thursday, June 25, 2020 at 5:00 p.m. Eastern Time. You will be emailed an individual link to attend the virtual Annual Meeting. Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, are posted at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI).

### **Registering to Attend the Annual Meeting as a Beneficial Owner**

We have been advised by Mediant Communications that beneficial stockholders as of the Record Date (i.e. shares held in “street name” through an intermediary, such as a bank or broker) who want to attend the Annual Meeting virtually must register in advance at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI) using the control number found on the proxy card or Notice of Internet Availability of Proxy Materials previously received by no later than Thursday, June 25, 2020 at 5:00 p.m. Eastern Time.

To attend the Annual Meeting virtually, beneficial owners must obtain a legal proxy from the holder of record and submit proof of legal proxy reflecting the number of shares of the Company common stock held as of the Record Date. Stockholders will then receive a confirmation of registration and an individual link to access the virtual Annual Meeting.

### **Asking Questions**

If you are attending the Annual Meeting as stockholder of record or beneficial owner, questions can be submitted either when you register to attend the Annual Meeting by accessing the meeting center at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI) and entering your control number or while you attend the Annual Meeting using the individual link you will receive after registering. Instructions on how to participate in the Annual Meeting are posted at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI).

### **Voting Shares**

Stockholders of record and beneficial owners who have obtained a legal proxy from the holder of record will be able to vote their shares electronically during the Annual Meeting by using their control number. Instructions on how to vote while participating in the Annual Meeting live via the Internet are posted at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI).

**Whether or not stockholders plan to virtually attend the Annual Meeting, the Company urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.**

The proxy materials, including the proxy card and Notice of Internet Availability of Proxy Materials, previously distributed along with the definitive proxy statement will not be updated to reflect the change in location and may continue to be used to vote shares in connection with the Annual Meeting.

### **List of Stockholders**

A list of stockholders entitled to vote at the Annual Meeting will be available for examination for any purpose germane to the Annual Meeting during normal business hours for ten days prior to the Annual Meeting at our corporate headquarters. To the extent office access is impracticable due to the recent COVID-19 pandemic, you may email us at [IR@proteostasis.com](mailto:IR@proteostasis.com) for alternative arrangements. The stockholder list will also be available during the Annual Meeting at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI). Instructions on how stockholders of record can view the stockholder list during the Annual Meeting are posted at [www.proxydocs.com/PTI](http://www.proxydocs.com/PTI).

### **About Proteostasis Therapeutics, Inc.**

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit [www.proteostasis.com](http://www.proteostasis.com).